Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
| Autor: | Cesare Mariotti, Michele Nicolai, Andrea Saitta, Ilir Arapi, Alfonso Giovannini, Vittorio Pirani, Piergiorgio Neri, Michele Maria Luchetti |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions Disease Pharmacology Toxicology Uveitis 03 medical and health sciences 0302 clinical medicine Antibodies monoclonal 0502 economics and business medicine Animals Humans Pharmacology (medical) Intensive care medicine business.industry 05 social sciences Biologic therapies Antibodies Monoclonal medicine.disease Biologic Agents Biological Therapy Safety profile 030221 ophthalmology & optometry 050211 marketing business Immunosuppressive Agents Medical literature |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1574-8863 |
| DOI: | 10.2174/1574886310666151014114925 |
| Popis: | Non-infectious uveitis can be a potentially sight threatening disease. Very recently, therapeutic strategies have turned towards a new methodology, which includes biologic agents. The introduction of biologic drugs has started a Copernican revolution in ophthalmology: biologic therapies represent a revolutionary option for those patients who present non-responder, sight threatening uveitis. The availability of these therapies has improved the uveitis outcome. The present review shows the most relevant medical literature on biologic agents in ophthalmology, such as tumor necrosis factor blockers, anti-interleukins and other related biologics. Several papers reported the efficacy of biologic agents in a large number of refractory uveitides, which suggest a promising role of biologic drugs for selected cases. On the other hand, the medical literature does not have consistent numbers yet, which hopefully will validate the promising preliminary results. Biologic agents are not only promising drugs for the treatment of nonresponder uveitis, but also they show an apparently favourable safety profile, although several topics remain unsolved: it is still not clear when commencing the treatment, which agent to choose, and the length of biologic therapy. Moreover, the high costs and the still not clear safety profile have very often limited their use only for severe, non-responder uveitis in highly specialized uveitis centres. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|